Schizophrenia Research and Treatment / 2018 / Article / Tab 4

Research Article

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Table 4

MetS among studied subjects on dual and mono antipsychotic therapy.

VariablesTotal Dual therapyMonotherapyOR (95 CI)p-value
n=236n=77n=159

Met / NCEP/ATP III
026(10.9)14(18.1)12(7.5)1
193(39.5)27(35.1)66(41.5)0.4(0.1-0.9)0.034
275(31.9)18(23.4)57(38.9)0.3(0.1-0.7)0.007
≥342(17.7)18(23.4)24(15.1)0.6(0.2-1.7)0.643
Met / IDF
016(6.7)8(10.4)8(5.0)1
171(30.3)22(28.6)49(30.8)0.5(0.2-1.4)0.159
278(32.7)22(28.6)56(35.2)0.4(0.1-1.12)0.138
≥371(30.3)25(32.4)46(28.9)0.6(0.2-1.6)0.393
Met / WHO
010(8.4)8(10.4)12(7.5)1
138(31.9)22(28.6)54(33.9)0.6(0.2-1.7)0.418
240(33.6)24(31.2)55(34.6)0.7(0.2-1.8)0.431
≥331(26.1)24(31.2)38(23.9)0.9(0.3-2.7)1.000

NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health Organization; MetS: metabolic syndrome; OR: odds ratio; CI: confidence interval.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.